The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy

Thurner, E.M.; Krenn-Pilko, S.; Langsenlehner, Uwe; Stojaković, Tatjana; Pichler, Martin; Gerger, Armin; Kapp, Karin S.; Langsenlehner, Tanja

doi:10.1016/j.ejca.2015.01.002

Cited by 52 publications

(42 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thurner et al [62] in 261 PC patients treated with external 3D conformational radiotherapy, analyzed the prognostic relevance of elevated plasma C-reactive protein (CRP) as a marker of inflammation. The optimal cut-off level for CRP was 8.6 mg/l.…”

Section: Prognostic Value Of Inflammation In Prostate Cancer Treated mentioning

confidence: 99%

“…In particular NLR but also PLR and CRP showed a significant and independent prognostic value for patients submitted to radiotherapy, either in terms of clinical progression or of overall survival, also after adjustment for Gleason score and clinical stage [59, 60]. In the intermediate and high risk classes as described by D’Amico et al, NLR and CRP are able to furthermore stratify cases in terms of clinical progression free survival [62]. …”

Section: Prognostic Value Of Inflammation In Prostate Cancer Treated mentioning

confidence: 99%

“…Elevated NLR and CRP levels may reflect increased concentrations of these pro-inflammatory cytokines that create a microenvironment favouring PC proliferation and metastatization despite radiotherapy [62]. Furthermore, raised CRP concentrations may produces increased serum levels of vascular endothelial growth factor (VEGF) [63, 64].…”

Section: Prognostic Value Of Inflammation In Prostate Cancer Treated mentioning

confidence: 99%

See 2 more Smart Citations

Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review

et al. 2016

View full text Add to dashboard Cite

Prostate is an immune-competent organ normally populated by inflammatory cells. Prostatic inflammation origin can be multi-factorial and there are some emerging evidences on its possible role as a factor involved in prostate cancer (PC) pathogenesis and progression.This review critically analyzes the role of inflammation as a prognostic factor for progression and aggressiveness of PC. We verified the last 10 years literature data on the association between inflammation and PC aggressiveness, or PC response to therapies.Several studies tried to correlate different inflammatory factors with the aggressiveness and metastatization of PC; all data sustain the role of inflammation in PC progression but they also produce confusion to identify a reliable clinical prognostic marker.Data on patients submitted to radical prostatectomy (RP) showed that cases with marked intraprostatic tissue inflammation are associated with higher rate of biochemical progression; systemic inflammation markers appear to have a significant prognostic value.Analyzing data on patients submitted to radiotherapy (RT) emerges a significant association between high neuthrophil to lymphocyte ratio (NLR) and decreased progression free survival and overall survival; also plateled to lymphocyte ratio (PLR) and C-reactive protein (CRP) have been proposed as significant prognostic factors for progression and overall survival.In patients submitted to androgen deprivation therapy (ADT), inflammation may drive castration resistant PC (CRPC) development by activation of STAT3 in PC cells. NLR has been proposed as independent predictor of overall survival in CRPC submitted to chemotherapy.Most of data are focused on markers related to systemic inflammation such as NLR and CRP, more than specifically to chronic prostatic inflammation. The suggestion is that these inflammatory parameters, also if not specific for prostatic inflammation and possibly influenced by several factors other than PC, can integrate with established prognostic factors.

show abstract

Section: Prognostic Value Of Inflammation In Prostate Cancer Treated mentioning

confidence: 99%

Section: Prognostic Value Of Inflammation In Prostate Cancer Treated mentioning

confidence: 99%

Section: Prognostic Value Of Inflammation In Prostate Cancer Treated mentioning

confidence: 99%

See 1 more Smart Citation

Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review

et al. 2016

View full text Add to dashboard Cite

show abstract

“…According to an early report, CRP is an independent prognostic factor for overall survival of patients with castration-resistant prostate cancer treated with docetaxel [29]. A recent study showed that elevated CRP level was associated with poor prognosis in prostate cancer patients treated with radiotherapy [30]. Accumulating data demonstrate that IL-8 is expressed by prostate cancer cells in which it contributes to increased angiogenesis, metastasis, and progression toward castration and chemotherapy resistance [31, 32].…”

Section: Discussionmentioning

confidence: 99%

Low vitamin D status is associated with inflammation in patients with prostate cancer

Xie

Chen

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Vitamin D deficiency has been associated with increased risks of prostate cancer. Nevertheless, the mechanisms remain unclear. The aim of this study was to analyze the association among prostate cancer, vitamin D status and inflammation. Sixty patients with newly diagnosed prostate cancer and 120 age-matched controls were recruited for this study. Vitamin D status was evaluated and serum inflammatory molecules were measured. Serum 25-(OH)D was lower in patients with prostate cancer. Moreover, serum 25(OH)D was lower in patients with severe prostate cancer than patients with mild and moderate prostate cancer. By contrast, serum C-reactive protein (CRP) and interleukin (IL)-8, two inflammatory molecules, were elevated in patients with prostate cancer. Serum 25-(OH)D was negatively correlated with serum CRP and IL-8 in patients with prostate cancer. Additional analysis showed that the percentage of vitamin D receptor positive nucleus in the prostate was reduced in patients with prostate cancer. By contrast, the percentage of nuclear factor kappa B p65-positive nucleus was elevated in patients with prostate cancer. Our results provide evidence that there is an association among prostate cancer, vitamin D deficiency and inflammatory signaling. Inflammation may be an important mediator for prostate cancer progression in patients with low vitamin D status.

show abstract

“…Prins et al [19] found that higher CRP was associated with a shorter survival in 119 CRPC patients. Thurner et al [25] evaluated 261 patients with prostate cancer treated with 3D-conformal radiotherapy. An elevated plasma CRP was identified as a prognostic factor for poor cancer-specific survival, OS and disease-free survival in prostate cancer patients undergoing radiotherapy.…”

Section: Discussionmentioning

confidence: 99%

C-Reactive Protein is a Prognostic Marker for Patients with Castration-Resistant Prostate Cancer

Liao

Chen²,

Lei³

2016

Oncol Res Treat

View full text Add to dashboard Cite

Introduction: As an acute-phase protein synthesized in response to systemic inflammation, the C-reactive protein (CRP) has been shown to be an independent prognostic factor for patients with castration-resistant prostate cancer (CRPC). The aim of this study was to investigate the association between CRP and progression-free survival (PFS), overall survival (OS) and radiological response in CRPC patients treated with docetaxel. Methods: 115 histologically confirmed CRPC patients who were treated with docetaxel chemotherapy from 2008 to 2013 were selected. Univariable and multivariable Cox regression models were used to predict the association of CRP as a dichotomous variable with PFS and OS after chemotherapy initiation. Results: None of the clinicopathological features were associated with the CRP. In Kaplan-Meier analysis, the median PFS (9.8 vs. 7.5 months, p < 0.001) and OS (26.5 vs. 13.5 months, p = 0.002) were higher in patients who did not have an elevated CRP than in those with an elevated CRP. In univariable analysis, the pretreatment CRP was significantly associated with PFS (p < 0.001) and OS (p = 0.003).In multivariable analysis, patients with a CRP > 8 mg/l were at significantly higher risk of tumor progress (hazard ratio (HR) 2.184; 95% confidence interval (CI) 1.401-3.403; p = 0.001) and death (HR 2.003; 95% CI 1.285-3.121; p = 0.002) than patients with a CRP ≤ 8 mg/l. Conclusions: CRP may be an important biomarker of PFS and OS in CRPC patients treated with docetaxel. The findings require validation in further prospective, large cohort-size studies.

show abstract

The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy

Cited by 52 publications

References 47 publications

Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review

Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review

Low vitamin D status is associated with inflammation in patients with prostate cancer

C-Reactive Protein is a Prognostic Marker for Patients with Castration-Resistant Prostate Cancer

Contact Info

Product

Resources

About